In subsets of patients with Barrett’s esophagus with dysplasia, therapeutics targeting HER2 or HER3 may be explored as a means of forestalling or preventing gastroesophageal carcinoma. This evidence concerns the gene ERBB2 and esophageal adenocarcinoma.